191 related articles for article (PubMed ID: 33684691)
1. Screening of SIRT6 inhibitors and activators: A novel activator has an impact on breast cancer cells.
Tenhunen J; Kučera T; Huovinen M; Küblbeck J; Bisenieks E; Vigante B; Ogle Z; Duburs G; Doležal M; Moaddel R; Lahtela-Kakkonen M; Rahnasto-Rilla M
Biomed Pharmacother; 2021 Jun; 138():111452. PubMed ID: 33684691
[TBL] [Abstract][Full Text] [Related]
2. Effects of galloflavin and ellagic acid on sirtuin 6 and its anti-tumorigenic activities.
Rahnasto-Rilla M; Järvenpää J; Huovinen M; Schroderus AM; Ihantola EL; Küblbeck J; Khadeer M; Moaddel R; Lahtela-Kakkonen M
Biomed Pharmacother; 2020 Nov; 131():110701. PubMed ID: 32905943
[TBL] [Abstract][Full Text] [Related]
3. Natural polyphenols as sirtuin 6 modulators.
Rahnasto-Rilla M; Tyni J; Huovinen M; Jarho E; Kulikowicz T; Ravichandran S; A Bohr V; Ferrucci L; Lahtela-Kakkonen M; Moaddel R
Sci Rep; 2018 Mar; 8(1):4163. PubMed ID: 29515203
[TBL] [Abstract][Full Text] [Related]
4. Structural Basis of Sirtuin 6 Activation by Synthetic Small Molecules.
You W; Rotili D; Li TM; Kambach C; Meleshin M; Schutkowski M; Chua KF; Mai A; Steegborn C
Angew Chem Int Ed Engl; 2017 Jan; 56(4):1007-1011. PubMed ID: 27990725
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for the activation and inhibition of Sirtuin 6 by quercetin and its derivatives.
You W; Zheng W; Weiss S; Chua KF; Steegborn C
Sci Rep; 2019 Dec; 9(1):19176. PubMed ID: 31844103
[TBL] [Abstract][Full Text] [Related]
6. Quinazolinedione SIRT6 inhibitors sensitize cancer cells to chemotherapeutics.
Sociali G; Galeno L; Parenti MD; Grozio A; Bauer I; Passalacqua M; Boero S; Donadini A; Millo E; Bellotti M; Sturla L; Damonte P; Puddu A; Ferroni C; Varchi G; Franceschi C; Ballestrero A; Poggi A; Bruzzone S; Nencioni A; Del Rio A
Eur J Med Chem; 2015 Sep; 102():530-9. PubMed ID: 26310895
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of activation for the sirtuin 6 protein deacylase.
Klein MA; Liu C; Kuznetsov VI; Feltenberger JB; Tang W; Denu JM
J Biol Chem; 2020 Jan; 295(5):1385-1399. PubMed ID: 31822559
[TBL] [Abstract][Full Text] [Related]
8. Quercetin based derivatives as sirtuin inhibitors.
Heger V; Tyni J; Hunyadi A; Horáková L; Lahtela-Kakkonen M; Rahnasto-Rilla M
Biomed Pharmacother; 2019 Mar; 111():1326-1333. PubMed ID: 30841446
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, Biological Investigation and Docking Study of Novel Chromen Derivatives as Anti-Cancer Agents.
Dube PN; Sakle NS; Dhawale SA; More SA; Mokale SN
Anticancer Agents Med Chem; 2019; 19(9):1150-1160. PubMed ID: 30848213
[TBL] [Abstract][Full Text] [Related]
10. Identification of a cellularly active SIRT6 allosteric activator.
Huang Z; Zhao J; Deng W; Chen Y; Shang J; Song K; Zhang L; Wang C; Lu S; Yang X; He B; Min J; Hu H; Tan M; Xu J; Zhang Q; Zhong J; Sun X; Mao Z; Lin H; Xiao M; Chin YE; Jiang H; Xu Y; Chen G; Zhang J
Nat Chem Biol; 2018 Dec; 14(12):1118-1126. PubMed ID: 30374165
[TBL] [Abstract][Full Text] [Related]
11. Studying SIRT6 regulation using H3K56 based substrate and small molecules.
Kokkonen P; Rahnasto-Rilla M; Mellini P; Jarho E; Lahtela-Kakkonen M; Kokkola T
Eur J Pharm Sci; 2014 Oct; 63():71-6. PubMed ID: 25004411
[TBL] [Abstract][Full Text] [Related]
12. A Comprehensive Analysis into the Therapeutic Application of Natural Products as SIRT6 Modulators in Alzheimer's Disease, Aging, Cancer, Inflammation, and Diabetes.
Akter R; Afrose A; Rahman MR; Chowdhury R; Nirzhor SSR; Khan RI; Kabir MT
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920726
[TBL] [Abstract][Full Text] [Related]
13. Benzimidazoles as new scaffold of sirtuin inhibitors: green synthesis, in vitro studies, molecular docking analysis and evaluation of their anti-cancer properties.
Yoon YK; Ali MA; Wei AC; Shirazi AN; Parang K; Choon TS
Eur J Med Chem; 2014 Aug; 83():448-54. PubMed ID: 24992072
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 5-(4-methylpiperazin-1-yl)-2-nitroaniline derivatives as a new class of SIRT6 inhibitors.
Sun W; Chen X; Huang S; Li W; Tian C; Yang S; Li L
Bioorg Med Chem Lett; 2020 Aug; 30(16):127215. PubMed ID: 32631504
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Potent Small-Molecule SIRT6 Activators: Structure-Activity Relationship and Anti-Pancreatic Ductal Adenocarcinoma Activity.
Chen X; Sun W; Huang S; Zhang H; Lin G; Li H; Qiao J; Li L; Yang S
J Med Chem; 2020 Sep; 63(18):10474-10495. PubMed ID: 32787077
[TBL] [Abstract][Full Text] [Related]
16. Structural Insight into the Interactions between Structurally Similar Inhibitors and SIRT6.
Zhao S; Zhu YY; Wang XY; Liu YS; Sun YX; Zhao QJ; Li HY
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32283646
[TBL] [Abstract][Full Text] [Related]
17. Anticancer effects of synthetic hexahydrobenzo [g]chromen-4-one derivatives on human breast cancer cell lines.
Pordeli M; Nakhjiri M; Safavi M; Ardestani SK; Foroumadi A
Breast Cancer; 2017 Mar; 24(2):299-311. PubMed ID: 27250840
[TBL] [Abstract][Full Text] [Related]
18. Emerging Therapeutic Potential of SIRT6 Modulators.
Fiorentino F; Mai A; Rotili D
J Med Chem; 2021 Jul; 64(14):9732-9758. PubMed ID: 34213345
[TBL] [Abstract][Full Text] [Related]
19. Expression of SIRT1, SIRT3 and SIRT6 Genes for Predicting Survival in Triple-Negative and Hormone Receptor-Positive Subtypes of Breast Cancer.
Uzelac B; Krivokuca A; Brankovic-Magic M; Magic Z; Susnjar S; Milovanovic Z; Supic G
Pathol Oncol Res; 2020 Oct; 26(4):2723-2731. PubMed ID: 32681437
[TBL] [Abstract][Full Text] [Related]
20. Structure-based identification of novel sirtuin inhibitors against triple negative breast cancer: An in silico and in vitro study.
Sinha S; Patel S; Athar M; Vora J; Chhabria MT; Jha PC; Shrivastava N
Int J Biol Macromol; 2019 Nov; 140():454-468. PubMed ID: 31404596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
